Tumour budding in head and neck squamous cell carcinoma – a systematic review
Corresponding Author
Alhadi Almangush
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Institute of Dentistry, University of Misurata, Misurata, Libya
Address for correspondence: A Almangush, Department of Pathology, Haartman Institute, University of Helsinki, FIN-00014, Finland. e-mail: [email protected]Search for more papers by this authorTuula Salo
Department of Diagnostics and Oral Medicine, Oulu University Hospital, and Medical Research Center, Oulu, Finland
Institute of Dentistry, University of Helsinki, Helsinki, Finland
These authors contributed equally to this study.
Search for more papers by this authorJaana Hagström
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Department of Oral Pathology, Institute of Dentistry, University of Helsinki, Helsinki, Finland
Search for more papers by this authorIlmo Leivo
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Department of Pathology, University of Turku, Turku, Finland
These authors contributed equally to this study.
Search for more papers by this authorCorresponding Author
Alhadi Almangush
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Institute of Dentistry, University of Misurata, Misurata, Libya
Address for correspondence: A Almangush, Department of Pathology, Haartman Institute, University of Helsinki, FIN-00014, Finland. e-mail: [email protected]Search for more papers by this authorTuula Salo
Department of Diagnostics and Oral Medicine, Oulu University Hospital, and Medical Research Center, Oulu, Finland
Institute of Dentistry, University of Helsinki, Helsinki, Finland
These authors contributed equally to this study.
Search for more papers by this authorJaana Hagström
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Department of Oral Pathology, Institute of Dentistry, University of Helsinki, Helsinki, Finland
Search for more papers by this authorIlmo Leivo
Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
Department of Pathology, University of Turku, Turku, Finland
These authors contributed equally to this study.
Search for more papers by this authorAbstract
Tumour budding is a specific type of invasive growth in carcinomas characterized by invading single tumour cells or small clusters of tumour cells (<5 cells) at the invasive front (IF). It has been documented in numerous publications during the past few decades, but its value as a prognostic marker in head and neck squamous cell carcinoma (HNSCC) has been analysed only recently. In this review we aimed to address the question of whether or not tumour budding has an impact upon the progression and prognosis of HNSCC. We systematically reviewed the databases of PubMed, Scopus and Web of Science for articles that studied tumour budding in squamous cell carcinoma of the head and neck region. The search was limited to articles published in the English literature before March 2014. A total of 122 hits were retrieved; however, only five reports met the inclusion criteria. The findings of these reports suggested a strong association between tumour budding and tumour progression, in addition to strong correlation with patient prognosis. Standardization of the scoring method and the risk stratification cut-off point is necessary before the inclusion of tumour budding in pathological reports during daily practice.
References
- 1Johnson NW, Warnakulasuriya S, Gupta PC et al. Global oral health inequalities in incidence and outcomes for oral cancer: causes and solutions. Adv. Dent. Res. 2011; 23; 237–246.
- 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63; 11–30.
- 3Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45; 309–316.
- 4Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55; 74–108.
- 5Helliwell TR. Molecular markers of metastasis in squamous carcinomas. J. Pathol. 2001; 194; 289–293.
10.1002/1096-9896(200107)194:3<289::AID-PATH912>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 6Brandwein-Gensler M, Smith RV. Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol. 2010; 4; 53–61.
- 7Hinni ML, Ferlito A, Brandwein-Gensler MS et al. Surgical margins in head and neck cancer: a contemporary review. Head Neck 2013; 35; 1362–1370.
- 8Marangon H Jr, Rocha VN, Leite CF, de Aguiar MC, Souza PE, Horta MC. Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J. Oral Pathol. Med. 2013; 43; 199–204.
- 9Wang C, Huang H, Huang Z et al. Tumor budding correlates with poor prognosis and epithelial–mesenchymal transition in tongue squamous cell carcinoma. J. Oral Pathol. Med. 2011; 40; 545–551.
- 10Almangush A, Bello IO, Keski-Santti H et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer. Head Neck 2013; 36; 811–818.
- 11Sarioglu S, Acara C, Akman FC et al. Tumor budding as a prognostic marker in laryngeal carcinoma. Pathol. Res. Pract. 2010; 206; 88–92.
- 12Luo WR, Gao F, Li SY, Yao KT. Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma. Histopathology 2012; 61; 1072–1081.
- 13Jakobsson PA, Eneroth CM, Killander D, Moberger G, Martensson B. Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol. Ther. Phys. Biol. 1973; 12; 1–8.
- 14Jakobsson PA. Histologic grading of malignancy and prognosis in glottic carcinoma of the larynx. Can. J. Otolaryngol. 1975; 4; 885–892.
- 15Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand. J. Dent. Res. 1987; 95; 229–249.
- 16Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J. Oral Pathol. Med. 1989; 18; 432–437.
- 17Martinez-Gimeno C, Rodriguez EM, Vila CN, Varela CL. Squamous cell carcinoma of the oral cavity: a clinicopathologic scoring system for evaluating risk of cervical lymph node metastasis. Laryngoscope 1995; 105; 728–733.
- 18Brandwein-Gensler M, Teixeira MS, Lewis CM et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am. J. Surg. Pathol. 2005; 29; 167–178.
- 19Chang YC, Nieh S, Chen SF, Jao SW, Lin YL, Fu E. Invasive pattern grading score designed as an independent prognostic indicator in oral squamous cell carcinoma. Histopathology 2010; 57; 295–303.
- 20Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50; 151–162.
- 21Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1; 651–661.
- 22Karamitopoulou E, Zlobec I, Kolzer V et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod. Pathol. 2013; 26; 295–301.
- 23Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol. Res. Pract. 2013; 209; 269–275.
- 24Kupferman ME, Jiffar T, El-Naggar A et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010; 29; 2047–2059.
- 25Guarino M, Rubino B, Ballabio G. The role of epithelial–mesenchymal transition in cancer pathology. Pathology 2007; 39; 305–318.
- 26Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell 2009; 139; 871–890.
- 27Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod. Pathol. 2012; 25; 1315–1325.
- 28Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br. J. Cancer 2012; 106; 1713–1717.
- 29Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 2011; 47; 840–846.
- 30Kawashiri S, Tanaka A, Noguchi N et al. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 2009; 31; 1346–1353.
- 31Kellermann MG, Sobral LM, da Silva SD et al. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology 2007; 51; 849–853.
- 32Marsh D, Suchak K, Moutasim KA et al. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 2011; 223; 470–481.
- 33Bello IO, Vered M, Dayan D et al. Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer. Oral Oncol. 2011; 47; 33–38.
- 34Salo T, Vered M, Bello IO et al. Insights into the role of components of the tumor microenvironment in oral carcinoma call for new therapeutic approaches. Exp. Cell Res. 2014; 325; 58–64.
- 35Patel V, Aldridge K, Ensley JF et al. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. Int. J. Cancer 2002; 99; 583–588.
- 36Gasparoni A, Della Casa M, Milillo L et al. Prognostic value of differential expression of Laminin-5 gamma2 in oral squamous cell carcinomas: correlation with survival. Oncol. Rep. 2007; 18; 793–800.
- 37Yusra, Semba S, Yokozaki H. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int. J. Oncol. 2012; 41; 201–210.
- 38Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front. Oncol. 2013; 2; 209.
- 39Wang X, Zhang J, Fan M et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT–PCR analysis with clinicopathological correlation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009; 107; 547–554.
- 40Mandal M, Myers JN, Lippman SM et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112; 2088–2100.
- 41Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod. Pathol. 2010; 23; 213–224.
- 42Fan CC, Wang TY, Cheng YA et al. Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2013; 139; 1735–1744.
- 43Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol. Clin. North Am. 2008; 41; 673–695, v.
- 44Mountzios G, Kostopoulos I, Kotoula V et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS ONE 2013; 8; e54048.
- 45Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4; 13–21.
- 46Xia WX, Ye YF, Lu X et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS ONE 2013; 8; e76958.
- 47Wu A, Luo W, Zhang Q et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett. 2013; 330; 181–189.
- 48Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127–132.
- 49Brown M, Sillah K, Griffiths EA et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010; 56; 893–899.
- 50Karamitopoulou E, Zlobec I, Born D et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur. J. Cancer 2013; 49; 1032–1039.
- 51Kanazawa H, Mitomi H, Nishiyama Y et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008; 10; 41–47.
- 52Lai YH, Wu LC, Li PS et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014; 16; 259–264.
- 53Teramoto H, Koike M, Tanaka C et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J. Surg. Oncol. 2013; 108; 42–46.
- 54Horcic M, Koelzer VH, Karamitopoulou E et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum. Pathol. 2013; 44; 697–705.
Citing Literature
